The earnings call revealed a mixed performance with some positive developments such as exceeding revenue guidance, strong cash flow, and new product launches, while facing challenges like year-over-year revenue decline and impacts from NIH funding delays and tariffs. However, the company has shown resilience by implementing cost efficiencies and addressing debt obligations.

Company Guidance

During the second quarter of 2025, Harvard Bioscience reported revenue of $20.5 million, surpassing their guidance range of $18 million to $20 million, primarily due to higher shipments in China. The gross margin stood at 56.4%, within their guidance of 55% to 57%, although it showed a slight decline from 57.2% in the previous year. Operating expenses decreased by $2 million, leading to an improvement in adjusted operating income to $1 million from $0.8 million in Q2 2024. Adjusted EBITDA increased to $1.5 million compared to $1.3 million in the same quarter of the previous year, driven by reduced operating expenses. Cash flow from operations was strong at $5.7 million year-to-date, with a $2.8 million contribution in Q2. The company also reduced net debt to $27.9 million from $32 million at year-end, reflecting a quarterly principal payment of $1 million. Looking ahead, they provided guidance for Q3 2025 with expected revenue between $19 million and $21 million and a gross margin range of 56% to 58%.

Positive Financial Metrics

Revenue for Q2 2025 was $20.5 million, exceeding guidance of $18 million to $20 million, primarily due to higher Chinese shipments. Adjusted operating income improved to $1 million compared to $0.8 million in Q2 2024. Adjusted EBITDA increased to $1.5 million from $1.3 million in the previous year.

Strong Cash Flow and Debt Reduction

Year-to-date cash flow from operations was $5.7 million, significantly higher than $0.6 million in the same period last year. Net debt decreased over $4 million from year-end to $27.9 million from $32 million.

Successful New Product Launches

New product pipeline includes the launch of the SoHo Telemetry platform with cardiac and neuromonitoring capabilities, and the VivaMARS automation pilot with Labcorp. Achieved $1 million in consumable revenue from BTX bioproduction.

Stability in Tariff Situation

Tariffs with China have stabilized at a 10% level, allowing orders and shipments to return to normal behavior after initial halts.

Harvard Bioscience (HBIO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HBIO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.01 / -	-0.02	―	―	―
Aug 11, 2025	2025 (Q2)	-0.03 / -0.01	0	―
May 12, 2025	2025 (Q1)	-0.04 / -0.01	0.02	-150.00% (-0.03)
Mar 12, 2025	2024 (Q4)	0.05 / 0.06	0.04	50.00% (+0.02)
Nov 07, 2024	2024 (Q3)	0.01 / -0.02	0.01	-300.00% (-0.03)
Aug 08, 2024	2024 (Q2)	0.05 / 0.00	0.04	―
May 07, 2024	2024 (Q1)	0.04 / 0.02	0.06	-66.67% (-0.04)
Mar 07, 2024	2023 (Q4)	0.05 / 0.04	0.04	0.00% (0.00)
Nov 07, 2023	2023 (Q3)	0.04 / 0.01	-0.01	200.00% (+0.02)
Aug 08, 2023	2023 (Q2)	0.06 / 0.04	0.05	-20.00% (-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

HBIO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$0.53	$0.48	-9.43%
May 12, 2025	$0.32	$0.35	+9.37%
Mar 12, 2025	$0.76	$0.68	-10.53%
Nov 07, 2024	$2.82	$2.39	-15.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Harvard Bioscience (HBIO) report earnings?

Harvard Bioscience (HBIO) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Harvard Bioscience (HBIO) earnings time?

Harvard Bioscience (HBIO) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is HBIO EPS forecast?

HBIO EPS forecast for the fiscal quarter 2025 (Q3) is 0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing